Viral Vector and Plasmid DNA Manufacturing Market
Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Assessment & Forecast
- By Product Type Plasmid DNA, Viral Vector, Non-viral Vector
- By Application Cancer, Genetic Disorder, Infectious Disease, Other Applications
- By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
|Forecast Years:||2023 - 2030|
|Historical Years:||2017 - 2021|
|Revenue 2022:||USD 697.16 Million|
|Revenue 2030:||USD 2285.58 Million|
|Revenue CAGR (2023 - 2030):||16.00%|
|Fastest Growing Region (2023 - 2030)||Asia Pacific|
|Largest Region (2022):||North America|
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
Frequently Asked Question
The global Viral Vector and Plasmid DNA Manufacturing valued at USD 697.16 Million in 2022 and is expected to reach USD 2285.58 Million in 2030 growing at a CAGR of 16.00%.
The prominent players in the market are Fujifilm Diosynth Biotechnologies (US), SIRION Biotech (Germany), Thermo Fisher Scientific (US), Merck KGaA Inc. (US), Cognate BioServices Inc. (Cobra Biologics) (US) are the major companies operating in Global Viral Vector and Plasmid DNA Manufacturing Market..
The market is project to grow at a CAGR of 16.00% between 2023 and 2030.
The driving factors of the Viral Vector and Plasmid DNA Manufacturing include
- Rising R&D Funding and Growing Initiatives
North America was the leading regional segment of the Viral Vector and Plasmid DNA Manufacturing in 2022.